When it comes to cancer, hide and seek is no game. Remaining hidden, cancer poses one of the greatest threats to life. But what if cancer couldn’t hide? What if there was a way to expose where it may be hiding and when it’s going to make its move?
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes.
Over 2.3 million women are diagnosed annually and every two minutes someone loses their life to breast cancer. Early detection is key in the fight against breast cancer where five-year survival rate increases to over 99% for stage 1 disease. Yet over 20% of breast cancers are missed in traditional mammogram screenings leading to advanced, late-stage, diagnoses for many breast cancer patients.
iCAD’s flagship product, the ProFound AI Breast Health Suite, is at the forefront of early cancer detection, density assessment and risk evaluation.
For over two decades, iCAD has pioneered AI-driven solutions for breast health. The ProFound Breast Health Suite encompasses a comprehensive suite of solutions, including Detection, Density, and Risk solutions, all aimed at enhancing accuracy and efficiency in cancer detection, providing certainty and peace of mind.
Trusted by thousands of providers serving millions of patients in over 50 countries, ProFound has analyzed more than 40 million mammograms globally in the last five years alone.
With a strong financial position, iCAD is poised to expand our reach, penetrate new market opportunities, and pave the way for a future where cancer can no longer hide.
Discover more about the power of iCAD’s Breast AI solutions at www.icadmed.com.
See iCAD in Action:
Comments